The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

post
Writing a Complex IND: The Top 3 Challenges and How to Avoid Them
Read More

post
Performing CMC Due Diligence for Molecule Licensing and Acquisitions
Read More

post
Why Protocol Amendments Matter: A Clinical Regulatory Medical Writing Perspective
Read More

post
Understanding FDA’s Real-Time Oncology Review (RTOR Medical Abbreviation) Program
Read More
Let's move from science to success.
Let’s Talk